Abstract

  Objective : To report the 13-year results of high-intensity focused ultrasound (HIFU) in the treatment of localized prostate cancer.
  Methods : A total of 872 men treated with Sonablate^® devices (Focus Surgery, Indianapolis, IN, USA) between January 1999 and October 2010 were included in this study. Biochemical failure was defined according to the Phoenix definition (prostate-specific antigen nadir : +2ng/ml).
  Results : The mean follow-up period for all patients was 50±32 months. The biochemical disease-free rates (BDFR) in patients in the low-, intermediate-, and highrisk groups at 5 and 10 years were 78, 62, and 47% and 70, 58, and 41%, respectively. The BDFR in patients treated with the latest device, SB 500 TCM, in the low-, intermediate-, and high-risk groups at 5 years were 95, 77, and 60%, respectively. The main complication was urethral stricture (18.3%).
  Conclusion : HIFU therapy is suggested to be minimally invasive and safe for patients with localized prostate cancer.